Table 2.
Demographics, Clinical, and Tumor Characteristics by Baseline Inventory of Depressive Symptomology
| Total | None (IDS <14 or unknown), N = 223, N (%) | Some (IDS ≥14), N = 92, N (%) | Total, N (%) | Overall OR (95% CI) |
|---|---|---|---|---|
| Age at interview (years) | ||||
| ≤65 | 41 (18.39) | 18 (19.57) | 59 (18.73) | Ref. |
| >65 | 182 (81.61) | 74 (80.43) | 256 (81.27) | 0.93 (0.50–1.72) |
| Race/ethnicity | ||||
| White (Hispanic and non-Hispanic) | 158 (70.85) | 63 (68.48) | 221 (70.16) | Ref. |
| African American | 45 (20.18) | 21 (22.83) | 66 (20.95) | 1.17 (0.65–2.12) |
| Asian | 20 (8.97) | 8 (8.70) | 28 (8.89) | 1.00 (0.42–2.40) |
| Stage at BC dx | ||||
| Stage 0 (DCIS) | 49 (21.97) | 12 (13.04) | 61 (19.37) | Ref. |
| Stages I–II | 174 (78.03) | 80 (86.96) | 254 (80.63) | 1.88 (0.95–3.72) |
| Years since diagnosis | ||||
| ≤5 | 109 (48.88) | 48 (52.17) | 157 (49.84) | Ref. |
| >5 | 114 (51.12) | 44 (47.83) | 158 (50.16) | 0.88 (0.54–1.43) |
| Radiation | ||||
| No | 105 (47.09) | 44 (47.83) | 149 (47.30) | Ref. |
| Yes | 118 (52.91) | 48 (52.17) | 166 (52.70) | 0.97 (0.60–1.58) |
| Hormonal (Tamoxifen/AIs) | ||||
| No | 114 (51.12) | 40 (43.48) | 154 (48.89) | Ref. |
| Yes | 109 (48.88) | 52 (56.52) | 161 (51.11) | 1.36 (0.83–2.22) |
| Chemotherapy | ||||
| No | 163 (73.09) | 59 (64.13) | 222 (70.48) | Ref. |
| Yes | 60 (26.91) | 33 (35.87) | 93 (29.52) | 1.52 (0.90–2.55) |
| Charlson Comorbidity Index | ||||
| 0 | 62 (27.80) | 25 (27.17) | 87 (27.62) | Ref. |
| 1–2 | 89 (39.91) | 36 (39.13) | 125 (39.68) | 1.00 (0.55–1.84) |
| 3+ | 72 (32.29) | 31 (33.70) | 103 (32.70) | 1.07 (0.57–2.00) |
| Physical activity | ||||
| Insufficiently active | 46 (22.77) | 26 (29.55) | 72 (24.83) | Ref. |
| Moderately active | 52 (25.74) | 25 (28.41) | 77 (26.55) | 0.85 (0.43–1.67) |
| Active | 104 (51.49) | 37 (42.05) | 141 (48.62) | 0.63 (0.34–1.16) |
| Unknown/missing | 21 (N/A) | 4 (N/A) | 25 (N/A) | N/A |
| RFQ | ||||
| Mean | 1.67 | 2.08 | 1.79 | |
| Median | 1.36 | 1.82 | 1.46 | p = 0.0003 |
| Lower, upper quartiles | 1.18–1.82 | 1.27–2.73 | 1.18–2.18 | |
| PSS | ||||
| None (0–13) | 82 (37.79) | 6 (6.52) | 88 (28.48) | Ref. |
| Some (14+) | 135 (62.21) | 86 (93.48) | 221 (71.52) | 8.71 (3.64–20.82) |
| Unknown/missing | 6 (N/A) | 0 (N/A) | 6 (N/A) | N/A |
| Vasomotor symptoms | ||||
| No | 96 (44.44) | 40 (44.44) | 136 (44.44) | Ref. |
| Yes | 120 (55.56) | 50 (55.56) | 170 (55.56) | 1.00 (0.61–1.64) |
| Unknown/missing | 7 (N/A) | 2 (N/A) | 9 (N/A) | N/A |
| Lifetime depression history | ||||
| No | 156 (69.96) | 55 (59.78) | 211 (66.98) | Ref. |
| Yes | 67 (30.04) | 37 (40.22) | 104 (33.02) | 1.57 (0.94–2.60) |
| Lifetime insomnia history | ||||
| No | 175 (78.48) | 44 (47.83) | 219 (69.52) | Ref. |
| Yes | 48 (21.52) | 48 (52.17) | 96 (30.48) | 3.98 (2.37–6.68) |
| Antidepressants (use post-BC dx) | ||||
| No | 194 (87.00) | 67 (72.83) | 261 (82.86) | Ref. |
| Yes | 29 (13.00) | 25 (27.17) | 54 (17.14) | 2.50 (1.37–4.56) |
| Sleep medication (use post-BC dx) | ||||
| No | 190 (85.20) | 73 (79.35) | 263 (83.49) | Ref. |
| Yes | 33 (14.80) | 19 (20.65) | 52 (16.51) | 1.50 (0.80–2.80) |
p-Values and percents are based on known values.
IDS, Inventory of Depressive Symptoms.